Praxis Precision Medicines

  • TickerPRAX
  • ISINUS74006W1080
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
PRAX Praxis Precisio... (Health Care)

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-5...

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE PRAX-562 Phase 2 clinical trial for treatment of DEEs expected to initiate in first half of 2022 CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ...

 PRESS RELEASE
PRAX Praxis Precisio... (Health Care)

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-5...

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for PRAX-562 for the treatment of SCN8A development and epileptic encephalopathy (SCN8A-DEE). “We des...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
PRAX Praxis Precisio... (Health Care)

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-5...

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE PRAX-562 Phase 2 clinical trial for treatment of DEEs expected to initiate in first half of 2022 CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ...

 PRESS RELEASE
PRAX Praxis Precisio... (Health Care)

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-5...

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for PRAX-562 for the treatment of SCN8A development and epileptic encephalopathy (SCN8A-DEE). “We des...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
PRAX Praxis Precisio... (Health Care)

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-5...

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE PRAX-562 Phase 2 clinical trial for treatment of DEEs expected to initiate in first half of 2022 CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ...

 PRESS RELEASE
PRAX Praxis Precisio... (Health Care)

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-5...

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for PRAX-562 for the treatment of SCN8A development and epileptic encephalopathy (SCN8A-DEE). “We des...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch